Invivyd (NASDAQ:IVVD) Receives Buy Rating from BTIG Research

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Performance

Shares of IVVD opened at $1.14 on Monday. Invivyd has a 52 week low of $0.48 and a 52 week high of $3.07. The firm has a market cap of $335.86 million, a P/E ratio of -3.68 and a beta of 0.63. The firm’s 50-day simple moving average is $1.39 and its 200 day simple moving average is $1.86.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The company had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. As a group, equities analysts forecast that Invivyd will post -0.5 earnings per share for the current year.

Institutional Trading of Invivyd

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in shares of Invivyd by 152.9% during the 1st quarter. Bank of America Corp DE now owns 962,386 shares of the company’s stock worth $1,251,000 after acquiring an additional 581,782 shares during the period. Stempoint Capital LP lifted its holdings in shares of Invivyd by 89.4% during the 1st quarter. Stempoint Capital LP now owns 1,874,546 shares of the company’s stock worth $2,437,000 after acquiring an additional 884,724 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Invivyd by 1.7% during the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after acquiring an additional 551,188 shares during the period. Eversept Partners LP lifted its holdings in shares of Invivyd by 6.4% during the 1st quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock worth $2,959,000 after acquiring an additional 136,219 shares during the period. Finally, SummitTX Capital L.P. bought a new stake in shares of Invivyd during the 1st quarter worth approximately $37,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.